Does sandostatin help with chronic diarrhea caused by carcinoid syndrome?

Does Sandostatin reduce diarrhea from carcinoid syndrome?

Sandostatin (octreotide) slows the release of hormones such as serotonin that carcinoid tumors secrete into the blood. Excess serotonin speeds gut motility and triggers watery stools, so lowering hormone levels often eases the diarrhea.

How quickly does relief start?

Most patients notice fewer daily stools within two to three days after the first injection. Full control may take one to two weeks as dosing is adjusted.

What dose is typically used?

The usual starting dose is 50 micrograms given under the skin two or three times a day. If symptoms persist, physicians increase the dose in steps up to 500 micrograms three times daily. Some patients move to a monthly long-acting injection once stable.

How long does the effect last?

Relief lasts as long as treatment continues. When the drug is stopped, hormone levels rise again and diarrhea usually returns within days.

What side effects are most common?

Injection-site pain, nausea, loose stools, and abdominal cramps occur in the first weeks. Gallstones, high or low blood sugar, and slowed heart rate can develop with longer use.

Can the drug stop working over time?

Some tumors escape control after months or years. Doctors then raise the dose, add interferon or everolimus, or consider liver-directed therapies.

When does the patent expire?

U.S. patents for the original octreotide formulation expired in 1998, and generic versions have been available since the early 2000s. The long-acting depot version (Sandostatin LAR) lost exclusivity in 2014. [1]

Who makes the generic versions?

Multiple manufacturers supply octreotide acetate injections, including Teva, Mylan, and Fresenius Kabi. Depot formulations are produced by Novartis and several authorized generics. [1]

[1] DrugPatentWatch.com